Company intelligence / Profile preview

Hirsch Industries

Richmond, Virginia, USA

Ownership: Private
Development stage: Other

Overview

Hirsch Industries, Inc. was a pharmaceutical company based in Richmond, Virginia, best known for developing and commercializing Lymphazurin (isosulfan blue 1%). Lymphazurin is a diagnostic contrast agent used in the identification of sentinel lymph nodes in patients with malignant melanoma and breast cancer. The company's technology played a pioneering role in the standardization of lymphatic mapping techniques in the early 1980s. Hirsch Industries was eventually succeeded by Covidien (now part of Medtronic), which held the New Drug Application (NDA) for Lymphazurin for several decades.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Pharma

Drug pipeline

1 asset

isosulfan blue

Approved

Beyond the preview

Go deeper on Hirsch Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hirsch Industries.

Explore the full profile